切换至 "中华医学电子期刊资源库"
高级检索
中华眼科医学杂志(电子版)

中华眼科医学杂志(电子版) ›› 2023, Vol. 13 ›› Issue (01) : 40 -44. doi: 10.3877/cma.j.issn.2095-2007.2023.01.008

综述

幼年特发性关节炎相关葡萄膜炎的研究进展
李文捷, 卢弘†()   
  1. 730000　兰州大学第一临床医学院2019级博士研究生；730000　兰州大学第一医院眼科
    730000　兰州大学第一医院眼科；100020　首都医科大学附属北京朝阳医院眼科
  • 收稿日期:2021-12-12 出版日期:2023-02-28
  • 通信作者: 卢弘
  • 基金资助:
    甘肃省自然科学基金项目(17JR5RA225); 甘肃省高等学校创新基金项目(2021B－023)

Research progress of uveitis associated with juvenile idiopathic arthritis

Wenjie Li, Hong Lu†()   

  1. Doctoral degree 2019, The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China; Department of Ophthalmology, The First Hospital of Lanzhou University, Lanzhou 730000, China
    Department of Ophthalmology, The First Hospital of Lanzhou University, Lanzhou 730000, China; Department of Ophthalmology, Beijing Chao Yang Hospital, Capital Medical University, Beijing 100083, China
  • Received:2021-12-12 Published:2023-02-28
  • Corresponding author: Hong Lu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李文捷, 卢弘. 幼年特发性关节炎相关葡萄膜炎的研究进展[J]. 中华眼科医学杂志(电子版), 2023, 13(01): 40-44.

Wenjie Li, Hong Lu. Research progress of uveitis associated with juvenile idiopathic arthritis[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(01): 40-44.

幼年特发性关节炎相关葡萄膜炎(JIA－U)是幼年特发性关节炎(JIA)常见的关节外表现。JIA－U通常表现为慢性前葡萄膜炎，发病隐匿，常伴随威胁视力的并发症。JIA－U治疗主要为控制JIA－U眼内炎症至无或最小活动态，并保持其静止，从而避免多种并发症的发生。了解JIA－U的发病机制和相关危险因素，可有利于及时治疗和最大程度地降低患者的视力损害程度。因此，本文中笔者现就JIA－U的流行特点、发病机制、临床表现、诊断及治疗进展进行综述。

关键词: 幼年特发性关节炎相关葡萄膜炎, 发病机制, 定期筛查, 诊断, 治疗

Juvenile idiopathic arthritis associated uveitis (JIA-U) is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA). JIA-U usually is characterized by chronic anterior uveitis, with insidious onset and often companying with vision-threatening complications. The goal of treatment for JIA-U is to reduce intraocular inflammation to zero or minimal activity to maintain immobility, which to be avoided various kinds of complications of JIA-U. It is of great benefit for ophthalmologists to understand the pathogenesis of JIA-U and associated risk factors, which to timely treat and reduce visual impairment with the greatest degree of effort. Therefore, the epidemic characteristics, pathogenesis, clinical manifestations, diagnosis and treatment of JIA-U were reviewed in this paper.

Key words: Juvenile idiopathic arthritis associated uveitis, Pathogenesis, Regular screening, Diagnosis, Treatment
图1 幼年特发性关节炎相关葡萄膜炎常见并发症的成像　图A示并发性角膜带状变性患者眼前节的彩色照相，可见睑裂区角膜带状变性，表现为角膜上皮层下前弹力层处灰色带状混浊，外侧与角膜缘之间有透明的角膜分隔；　图B示并发性白内障患者眼前节的彩色照相，可见虹膜与晶状体前囊膜粘连，前囊膜表面色素沉着，晶状体灰白色混浊；图C示并发黄斑水肿患者的光学相干断层扫描成像，可见黄斑鼻侧视网膜神经上皮层脱离
图2 幼年特发性关节炎相关葡萄膜炎诊断筛查策略的示意图
[1]
Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001[J]. J Rheumatol, 2004, 31(2): 390－392.
[2]
Carlsson E, Beresford MW, Ramanan AV, et al. Juvenile idiopathic arthritis associated uveitis[J]. Children (Basel), 2021, 8(8): 646.
[3]
Sen ES, Ramanan AV. Juvenile idiopathic arthritis－associated uveitis[J]. Clin Immunol, 2020, 211: 108322.
[4]
Consolaro A, Giancane G, Alongi A, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study[J]. Lancet Child Adolesc Health, 2019, 3(4): 255－263.
[5]
Clarke SLN, Mageean KS, Carlton H, et al. Environmental risk factors associated with juvenile idiopathic arthritis associated uveitis: a systematic review of the literature[J]. J Ophthalmic Inflamm Infect, 2021, PMID: 34027581.
[6]
Wei L, Zhou Q, Hou S, et al. MicroRNA－146a and Ets－1 gene polymorphisms are associated with pediatric uveitis[J]. PLoS One, 2014, 9(3): e91199.
[7]
Deng J, Tan H, Hu J, et al. Genetic aspects of idiopathic paediatric uveitis and juvenile idiopathic arthritis associated uveitis in Chinese Han[J]. Br J Ophthalmol, 2020, 104(3): 443－447.
[8]
Wennink RAW, de Boer JH, Hiddingh S, et al. Next－Generation HLA sequence analysis uncovers shared risk alleles between clinically distinct forms of childhood Uveitis[J]. Invest Ophthalmol Vis Sci, 2021, PMID: 34254975.
[9]
Walscheid K, Neekamp L, Heiligenhaus A, et al. Increased circulating proinflammatory T lymphocytes in children with different forms of anterior uveitis: results from a pilot study[J]. Ocul Immunol Inflamm, 2019, 27(5): 788－797.
[10]
Walscheid K, Neekamp L, Heiligenhaus A, et al. Peripheral blood monocytes reveal an activated phenotype in pediatric uveitis[J]. Clin Immunol, 2018, 190: 84－88.
[11]
Kalinina AV, van Dijk MR, de Boer JH. Infiltration of plasma cells in the iris of children with ana－positive anterior uveitis[J]. Invest Ophthalmol Vis Sci, 2015, 56(11): 6770－6778.
[12]
Wildschütz L, Ackermann D, Witten A, et al. Transcriptomic and proteomic analysis of iris tissue and aqueous humor in juvenile idiopathic arthritis－associated uveitis[J]. J Autoimmun, 2019, 100: 75－83.
[13]
Wennink RAW, Pandit A, Haasnoot AJW, et al. Whole transcriptome analysis reveals heterogeneity in B cell memory populations in patients with juvenile idiopathic arthritis－associated uveitis[J]. Front Immunol, 2020, PMID: 33042130.
[14]
Busch M, Wefelmeyer KL, Walscheid K, et al. Identification of ocular autoantigens associated with juvenile idiopathic arthritis－associated uveitis[J]. Front Immunol, 2019, PMID: 31447836.
[15]
Wang J, Wu H, Liu X, et al. Effect of LPS on cytokine secretion from peripheral blood monocytes in juvenile idiopathic arthritis－associated uveitis patients with positive antinuclear antibody[J]. J Immunol Res, 2021, PMID: 34056011.
[16]
Sijssens KM, Rijkers GT, Rothova A, et al. Cytokines, chemokines and soluble adhesion molecules in aqueous humor of children with uveitis[J]. Exp Eye Res, 2007, 85(4): 443－449.
[17]
Drozdova EA, Yadykina EV, Mezentseva EA, et al. Cytokine profile changes in children with juvenile idiopathic arthritis－associated uveitis[J]. Vestn Oftalmol, 2017, 133(1): 27－31.
[18]
Walscheid K, Heiligenhaus A, Holzinger D, et al. Elevated S100A8/A9 and S100A12 serum levels reflect intraocular inflammation in juvenile idiopathic arthritis－associated uveitis: results from a pilot study[J]. Invest Ophthalmol Vis Sci, 2015, 56(13): 7653－7660.
[19]
Haasnoot AM, Kuiper JJ, Hiddingh S, et al. Ocular fluid analysis in children reveals interleukin－29/interferon－λ1 as a biomarker for juvenile idiopathic arthritis－associated uveitis[J]. Arthritis Rheumatol, 2016, 68(7): 1769－1779.
[20]
Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis－associated uveitis[J]. Pediatr Rheumatol Online J, 2016, 14(1): 27.
[21]
Cosickic A, Halilbasic M, Selimovic A, et al. Uveitis associated with juvenile idiopathic arthritis, our observations[J]. Med Arch, 2017, 71(1): 52－55.
[22]
Chen JL, Abiri P, Tsui E. Recent advances in the treatment of juvenile idiopathic arthritis－associated uveitis[J]. Ther Adv Ophthalmol, 2021, PMID: 33681703.
[23]
American Academy of Pediatrics Section on Rheumatology and Section on Ophthalmology. Guidelines for ophthalmologic examinations in children with juvenile rheumatoid arthritis[J]. Pediatrics, 1993, 92(2): 295－296.
[24]
Angeles－Han ST, Ringold S, Beukelman T, et al. 2019 American college of rheumatology/arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis－associated uveitis[J]. Arthritis Care Res, 2019, 71(6): 703－716.
[25]
Liebling EJ, Faig W, Chang JC, et al. Temporal relationship between juvenile idiopathic arthritis disease activity and uveitis disease activity[J]. Arthritis Care Res (Hoboken), 2022, 74(3): 349－354.
[26]
Cassidy J, Kivlin J, Lindsley C, et al. Ophthalmologic examinations in children with juvenile rheumatoid arthritis[J]. Pediatrics, 2006, 117(5): 1843－1845.
[27]
Thomas AS. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics[J]. Curr Opin Ophthalmol, 2019, 30(3): 138－150.
[28]
Angeles－Han ST, McCracken C, Yeh S, et al. Characteristics of a cohort of children with juvenile idiopathic arthritis and JIA－associated uveitis[J]. Pediatr Rheumatol Online J, 2015, PMID: 26031738.
[29]
Constantin T, Foeldvari I, Anton J, et al. Consensus－based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative[J]. Ann Rheum Dis, 2018, 77(8): 1107－1117.
[30]
侯蕾，刘礼初，邢基斯. 36例幼年特发性关节炎病例回顾性研究[J]. 世界中西医结合杂志，2015，10(4)：511－513，517.
[31]
Kostik MM, Gaidar EV, Hynnes AY, et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use[J]. Clin Exp Rheumatol, 2016, 34(4): 714－718.
[32]
Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta－analysis approach[J]. Rheumatology (Oxford), 2013, 52(5): 825－831.
[33]
Wieringa WG, Armbrust W, Legger GE, et al. Efficacy of high－dose methotrexate in pediatric non－infectious uveitis[J]. Ocul Immunol Inflamm, 2019, 27(8): 1305－1313.
[34]
Tirelli F, Zannin ME, Vittadello F, et al. Methotrexate monotherapy in juvenile idiopathic arthritis associated uveitis: myth or reality？[J]. Ocul Immunol Inflamm, 2022, PMID: 34287104.
[35]
Simonini G, Bracaglia C, Cattalini M, et al. Predictors of relapse after discontinuing systemic treatment in childhood autoimmune chronic uveitis[J]. J Rheumatol, 2017, 44(6): 822－826.
[36]
Cheung CSY, Mireskandari K, Ali A, et al. Earlier use of systemic immunosuppression is associated with fewer ophthalmic surgeries in paediatric non－infectious uveitis[J]. Br J Ophthalmol, 2020, 104(7): 938－942.
[37]
Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children[J]. Br J Ophthalmol, 2007, 91(2): 180－184.
[38]
Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis[J]. Br J Ophthalmol, 2011, 95(2): 209－213.
[39]
Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin a therapy in refractory non－infectious childhood uveitis[J]. Br J Ophthalmol, 1998, 82(7): 737－742.
[40]
Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double－blind, randomised, placebo－controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis－associated anterior uveitis[J]. Ann Rheum Dis, 2018, 77(7): 1003－1011.
[41]
Ramanan AV, Dick AD, Jones AP, et al. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT[J]. Health Technol Assess, 2019, PMID: 31033434.
[42]
Leinonen ST, Aalto K, Kotaniemi KM, et al. Anti－adalimumab antibodies in juvenile idiopathic arthritis－related uveitis[J]. Clin Exp Rheumatol, 2017, 35(6): 1043－1046.
[43]
Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis[J]. J Rheumatol, 2016, 43(12): 2183－2188.
[44]
Maleki A, Manhapra A, Asgari S, et al. Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis associated uveitis[J]. Ocul Immunol Inflamm, 2021, 29(1): 14－20.
[45]
Mesquida M, Molins B, Llorenç V, et al. Long－term effects of tocilizumab therapy for refractory uveitis－related macular edema[J]. Ophthalmology, 2014, 121(12): 2380－2386.
[46]
Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti－TNF refractory juvenile idiopathic arthritis－associated uveitis (APTITUDE): a multicentre, single－arm, phase 2 trial[J]. Lancet Rheumatol, 2020, 2(3): e135－e141.
[47]
Birolo C, Zannin ME, Arsenyeva S, et al. Comparable efficacy of abatacept used as first－line or second－line biological agent for severe juvenile idiopathic arthritis－related uveitis[J]. J Rheumatol, 2016, 43(11): 2068－2073.
[48]
Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases[J]. Nat Rev Drug Discov, 2017, 16(12): 843－862.
[49]
Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis[J]. Rheumatology (Oxford), 2019, 58(S1): i17－i26.
[50]
Bing SJ, Lyu C, Xu B, et al. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells[J]. Mol Vis, 2020, 26: 641－651.
[51]
Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis[J]. Ocul Immunol Inflamm, 2019, 27(8): 1232－1234.
[52]
Miserocchi E, Giuffrè C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis－associated uveitis[J]. Clin Rheumatol, 2020, 39(3): 847－851.
[53]
Miserocchi E, Modorati G, Berchicci L, et al. Long－term treatment with rituximab in severe juvenile idiopathic arthritis－associated uveitis[J]. Br J Ophthalmol, 2016, 100(6): 782－786.
[54]
Gaffney KJ, Dahl EM, Stanton MP, et al. Rapid－infusion rituximab in a pediatric population[J]. J Pediatr Pharmacol Ther, 2020, 25(3): 215－219.
[55]
Maleki A, Anesi SD, Look－Why S, et al. Pediatric uveitis: A comprehensive review[J]. Surv Ophthalmol, 2022, 67(2): 510－529.
[1] 杨水华, 何桂丹, 覃桂灿, 梁蒙凤, 罗艳合, 李雪芹, 唐娟松. 胎儿孤立性完全型肺静脉异位引流的超声心动图特征及高分辨率血流联合时间-空间相关成像的应用[J]. 中华医学超声杂志（电子版）, 2023, 20(10): 1061-1067.
[2] 彭旭, 邵永孚, 李铎, 邹瑞, 邢贞明. 结肠肝曲癌的诊断和外科治疗[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 108-110.
[3] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[4] 李智铭, 郭晨明, 庄晓晨, 候雪琴, 高军喜. 早期乳腺癌超声造影定性及定量指标的对比研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 639-643.
[5] 张海涛, 康婵娟, 翟静洁. 胰管支架置入治疗急性胆源性胰腺炎效果观察[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 654-657.
[6] 杨雪, 张伟, 尚培中, 宋创业, 尚丹丹, 张蔚. 胆囊十二指肠瘘结石经瘘口排出后自愈一例报道[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 707-708.
[7] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[8] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[9] 许丁伟, 马江云, 李新成, 黄洁. Alagille综合征疑诊为先天性胆道闭锁一例并文献复习[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 681-687.
[10] 袁媛, 赵良平, 刘智慧, 张丽萍, 谭丽梅, 閤梦琴. 子宫内膜癌组织中miR-25-3p、PTEN的表达及与病理参数的关系[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1016-1020.
[11] 陆志峰, 周佳佳, 梁舒. 虚拟现实技术在治疗弱视中的临床应用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 891-895.
[12] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[13] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
[14] 周婷, 孙培培, 张二明, 安欣华, 向平超. 北京市石景山区40岁及以上居民慢性阻塞性肺疾病诊断现状调查[J]. 中华临床医师杂志(电子版), 2023, 17(07): 790-797.
[15] 符梅沙, 周玉华, 李慧, 薛春颜. 淋巴细胞免疫治疗对复发性流产患者外周血T淋巴细胞亚群分布与PD1/PD-L1表达的影响及意义[J]. 中华临床医师杂志(电子版), 2023, 17(06): 726-730.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号